Patricia A Weber, DrPH - Program Director, National Cancer Institute SBIR Development Center
Dr. Weber completed her Masters and Doctorate in Public Health with an emphasis in Biomedical Sciences at the School of Public Health, University of California at Berkeley. She was Director of Microbiology and Immunology at a San Diego-based biotech company that focused on the discovery and development of peptide therapeutics. She then moved to western Montana where she was the Team Leader of Cardiovascular Pharmacology at Ribi ImmunoChem Research (currently GSK) in Hamilton, MT. In addition to managing the preclinical development efforts of an intravenous biological product for the prevention of ischemia/reperfusion injury associated with cardiopulmonary bypass procedures, she also worked on licensing the therapeutic to potential pharmaceutical partners. She joined the International Heart Institute of Montana in 2000 where she managed the Tissue Engineering and Surgical Research Laboratories. Her work involved the preclinical development of cardiovascular devices including heart valves, bioengineered blood vessels and novel, stent-based devices. She implemented Good Laboratory Practices (GLP), thus allowing the Institute to perform studies to be included in submissions to the FDA for approval of new medical devices. Dr Weber began work at the National Institute of Health in the National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center in Oct of 2008. The SBIR Development Center is a division at the NCI that manages more than $117 million in technology projects within the small business community to accelerate the progress of cancer research. Her area of emphasis is in cancer prevention, digital health, therapeutics, and biologics.
Thirteen new contract topics available with an application deadline of Nov 13:
When & Where